Erlizumab (Anti-Integrin b2 / ITGB2 / CD18)
Erlizumab (Anti-Integrin b2 / ITGB2 / CD18) (A2712-GRP)
Products
Description
Erlizumab (anti-Integrin b2 / ITGB2 / CD18) is a humanized monoclonal antibody targeted against Integrin beta-2 and used as a therapy for hemorrhagic shock. MW: 146.66 kD.
Specifications
| Manufacturer | Selleck Chemicals LLC |
|---|---|
| Manufacturer Cat# | A2712 |
| Target | Integrin |